Simplify MAb Production by Eliminating Contaminating IgG and Reducing Cost
News Apr 28, 2011
InVitria and Lampire Biological are hosting a webinar to share a strategy to eliminate contaminating IgG’s from serum while reducing monoclonal antibody (MAb) production costs. The webinar will be broadcast live at 11:30am EST on May 10, 2011 and will be archived on InVitria’s website for future viewing.
MAbs are a valuable asset in the development of future of medicines, from use as basic research tools to large-scale biotherapeutics. Given the versatility and convenience offered by using hybridomas to produce MAbs, scientists continue to expand upon the vast potential these proteins represent.
However, limitations in hybridoma productivity and costly purification processes associated with contaminating materials, such as IgG from bovine serum used in hybridoma culture medium, can significantly increase MAb costs.
During this webinar, the challenges facing non-therapeutic MAb production will be discussed. Annette Flood, Monoclonal Department Manager, Lampire Biological Laboratory will present a case study to show Lampire’s success in reducing costs and improving performance in serum-free hybridoma cell culture conditions and Mab production.
“The development of technologies to improve the consistency and purification of monoclonal antibody production is key to reducing manufacturing costs,” said Brittany Medbery, InVitria. “In this webinar we will share the successful implementation of this technology.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019